Relationship between Biofilm-Formation, Phenotypic Virulence Factors and Antibiotic Resistance in Environmental Pseudomonas aeruginosa

Payam Behzadi, Máríó Gajdács, Péter Pallós, Boglárka Önodi, Anette Stájer, Danica Matusovits, Krisztina Kárpáti, Katalin Burián, Basem Battah, Marco Ferrari, Carlo Doria, Gianfilippo Caggiari, Ameer Khusro, Stefania Zanetti and Matthew Cavino Donadu

Abstract: The formation of a protective biofilm by Pseudomonas aeruginosa (PA) is one of the hallmarks of their survival both in vivo and in harsh environmental conditions, thus, biofilm-eradication has relevance from therapeutic perspectives and for infection control. The aim of our study was to investigate the possible relationship between antibiotic resistance, biofilm-forming capacity and virulence factors in n = 166 PA isolates of environmental origin. Antimicrobial susceptibility testing and the phenotypic detection of resistance determinants were carried out using standard protocols. The biofilm-forming capacity of PA was tested using a standardized crystal violet microtiter plate-based method. Motility (swimming, swarming, and twitching) and siderophore production of the isolates were also assessed. Resistance rates were highest for ciprofloxacin (46.98%), levofloxacin (45.18%), ceftazidime (31.92%) and cefepime (30.12%); 19.28% of isolates met the criteria to be classified as multidrug-resistant (MDR). Efflux pump overexpression, AmpC overexpression, and modified Hodge-test positivity were noted in 28.31%, 18.07% and 3.61%, respectively. 22.89% of isolates were positive for siderophore production. The importance of PA as a pathogen in chronic and healthcare-associated infections has been described extensively, while there is increasing awareness of PA as an environmental agent in agriculture and aquaculture. Additional studies in this field would be an important undertaking to understand the interrelated nature of biofilm production and antimicrobial resistance, as these insights may become relevant bases for developing novel therapeutics and eradication strategies against PA.
Keywords: Pseudomonas aeruginosa; antimicrobial resistance; MDR; environmental; biofilm; crystal violet; motility; siderophores; One Health; non-fermenting; phenotypic assay

1. Introduction

The genus *Pseudomonas* (a member of the *Pseudomonatoda* phylum as per recent taxonomic revisions) currently consist of around 300 different species, characterized by being motile, obligate aerobic, oxidase-positive, non-fermenting Gram-negative rods [1,2]. Although *P. aeruginosa* (PA) is the most commonly isolated species from both human infections and from environmental sources, other species of the genus have also been highlighted as relevant causative agents for food and pharmaceutical spoilage (e.g., *P. putida*, *P. fluorescens*), and as plant pathogens (*P. plecoglossicida*, *P. syringae* and *P. viridiflava*) and fish (*P. anguilliseptica* and *P. baetica*) [3–5]. *Pseudomonas* spp. are ubiquitous in the environment—although in low abundance—but their isolation correlates with rates of anthropogenic influence; these bacteria are commonly found in aquatic sources, sediments, plants and soil, in addition to man-made sites like farming regions and hospital environments [6,7]. Their universal presence in a wide variety of habitats may be owed to their non-fastidious growth requirements and their incredible adaptability to many different environmental factors [8]. This is made possible by considerable genomic plasticity (e.g., PA has a genome size of ~5.5–7 Mb) and an interconnected quorum sensing (QS) regulatory network of four pathways (*pqs*, *rhl*, *las* and *iqs*), tightly controlling metabolic processes and the expression of many virulence factors (such as toxins, enzymes, pigment, and motility) [9–11]. The formation of a protective biofilm by *Pseudomonas* spp. is one of the hallmarks of their survival both in vivo (against antibiotics and immune cells) and in harsh environmental conditions, thus, biofilm-eradication has relevance from therapeutic and infection control perspectives [12,13].

The emergence of multidrug resistance (MDR) in bacteria has become one of the most daunting challenges of the 21st century, due to the increasing prevalence of difficult-to-treat infections and the lack of relevant therapeutic alternatives [14–16]. The magnitude of the issue has also been identified by political leaders, exemplified by the recent commitment of the G7 Nations to resistance surveillance and to invest in antimicrobial research [17]. PA is an important causative agent of serious infections in hospitalized and immunocompromised individuals, often with a high mortality rate (highest among non-fermenters) [18,19]; common clinical manifestations include ventilator-associated pneumonia, bacteremia, keratitis, swimmer’s ear, urinary tract infections, catheter-associated infections and skin and soft tissue infections (often resulting from surgery or burns) [2,8,20]. MDR in PA often results from a complex interplay of intrinsic resistance mechanisms and acquired resistance to the main antibiotic groups relevant in PA infections (i.e., anti-pseudomonal β-lactams, fluoroquinolones, aminoglycosides and polymyxins) [2,21]. In the United States (according to 2017 data), MDR PA has caused ~33,000 infections and 2700 deaths among hospitalized patients, while in the EU/EEA region (according to 2016–2020 surveillance data), resistance in PA to ≥3 antimicrobials ranged between 0–47.1% [22,23]. Carbapenem-resistant PA (CR-PA) is also included as a “Priority 1: Critical” pathogen on the World Health Organization (WHO) Priority Pathogens List [24].

In recent years, many studies have been published detailing the possible correlation or co-occurrence of the antibiotic-resistant (or the MDR) phenotype and biofilm-formation in various bacterial genera [25,26]; biofilm provides a form of “adaptive” resistance against antimicrobial drugs (resulting in lower capacity for diffusion, low oxygen tension and emergence of dormant phenotypes), in addition to some researchers suggesting common regulatory mechanisms behind biofilm-production and the expression of resistance genes [27,28]. However, the presently available evidence is contradictory and is often influenced by the heterogeneity of bacterial isolates and the methods used [29]. For example, Azizi and colleagues showed that *Acinetobacter baumannii* carrying the β-lactamase
PER-1 produced more extensive biofilm—compared to non-carriers—due to an advantage in the capacity of epithelial attachment, a critical factor in early biofilm-formation [30]. On the other hand, in the case of PA, Gallant and colleagues noted an inverse relationship between the carriage of the TEM-1 β-lactamase, adhesion potential and subsequent biofilm-formation [31].

In a previous in vitro study, we assessed the correlation between biofilm-forming capacity, antimicrobial resistance and the expression of phenotypic virulence factors in randomly-selected clinical PA isolates (n = 302) [32]; in the study, no associations were found between MDR-status of the isolates and their propensity to form biofilm. Furthermore, no relationship was seen between biofilm formation, various motility types and pigment production (with the exception of pyocyanin) in these experiments. To complement and confirm our previous findings, our aim was to investigate the possible relationship between antibiotic resistance, biofilm-forming capacity and virulence factors in PA isolates of environmental origin. Our working hypotheses—based on our previous findings—were as follows: (i) the majority of environmental PA isolates are strong biofilm-producers; (ii) MDR is not a predictor of biofilm-forming capacity; (iii) there is no significant association between biofilm-formation and the presence of other virulence-determinants.

2. Materials and Methods

2.1. Sample Size Determination

The sample size of environmental PA isolates required for this descriptive study was determined using the formula below (1), based on the methodology described by Thrusfield et al. [33], where \( n \) was the calculated sample size, \( z \) was the desired level of confidence (1.96), \( i \) was the standard sampling error (5%), and \( p \) was the estimated prevalence set at 10%. The minimum required sample size \( (n = 138) \) was increased by 20% for added contingency [34], thus the required sample size of \( n = 166 \) was determined.

\[
n = \frac{z^2 p (1-p)}{i^2}
\]  

(1)

2.2. Collection of Isolates

A total of one hundred and sixty-six (\( n = 166 \)) PA isolates were included in the study, which was obtained from strain collections of environmental origins. The bacteria included were isolated from both outdoors (e.g., surface water, sediments, soil, agricultural sources and plants) and from surfaces with high rates of human contact (e.g., handles, steel and rubber surfaces) in Sassari (Italy) and Szeged (Hungary). Environmental sampling of these isolates was carried out via established protocols, described previously [35]. As a rule of thumb, only one PA isolate per source was included [36]. During the experiments, PA ATCC 27853 (characterized by limited biofilm-production and MDR), and PA PAE 170022 (characterized by strong biofilm-production and susceptibility to antibiotics) were used as control strains, which were obtained from the American Type Culture Collection (ATCC; Manassas, VI, USA) [32]. Stock cultures were stored at \(-80{^\circ}C\) in a cryopreservation medium (700 µL trypticase soy broth + 300 µL 50% glycerol) until further use.

2.3. Identification of Isolates

PA isolates were re-identified to the species level before inclusion in further experiments. Identification was carried out using matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI–TOF MS), using a MicroFlex MALDI Biotype (Bruker Daltonics, Bremen, Germany); the technical details of the mass spectrometry measurements were described previously [32]. Spectra analysis was carried out with the MALDI Biotyper RTC 3.1 software and the MALDI Biotyper Library 3.1 (Bruker Daltonics, Bremen, Germany). During analysis, a \( \log(\text{score}) \) value was assigned to all isolates, indicating the reliability of identification: a score \( \geq 2.30 \) corresponded to reliable species-level identification [37].
2.4. Antimicrobial Susceptibility Testing

Susceptibility testing for relevant anti-pseudomonal antibiotics was carried out using the disk diffusion method (Oxoid, Basingstoke, UK) and E-tests (Liofilchem, Roseto degli Abruzzi, Italy) on Mueller-Hinton agar plates (bioMérieux, Marcy-l’Étoile, France) including amikacin, ceftazidime, cefepime, ciprofloxacin, gentamicin, imipenem, levofloxacin and meropenem. Colistin susceptibility was performed using the broth microdilution assay in cation-adjusted Mueller-Hinton broth (Merlin Diagnostika GmbH, Bremen, Germany). Interpretation of the results was based on the standards and breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) v. 11.0 [38]. Results indicating “susceptible, increased exposure (I)” were grouped with and reported as susceptible (S) [39]. Classification of the isolates as MDR (resistance to at least one agent in ≥3 antibiotic groups) was based on Magiorakos et al. [40]. A multiple antibiotic resistance (MAR) index—ranging between 0 and 1—was calculated by dividing the total number of detected resistance to antimicrobials for each isolate by the total number of tested antimicrobials [41].

2.5. Phenotypic Detection of β-Lactamases

In the case of detecting ceftazidime resistance, the overexpression of AmpC β-lactamase enzymes was tested using an agar plate method, as described previously [42]. In this assay, cloxacillin (250 µg/mL in the agar base) was used, as this antibiotic is able to inhibit the effects of AmpC β-lactamases [43]. An isolate was considered positive for AmpC-overexpression if a two-fold difference in ceftazidime MICs (measured by E-tests) were observed with or without the presence of cloxacillin [42]. Isolates were screened for carbapenemase-production—if the inhibition zone diameters around meropenem disks were 23 mm ≥ (intermediate: 23–18 mm, or resistant <19 mm)—using the modified Hodge (cloverleaf) test optimized for PA, as previously described [44,45]. During the assay, 10 µg meropenem (Oxoid, Basingstoke, UK) disks were used, while Escherichia coli ATCC 25922 was used as an indicator organism [46].

2.6. Detection of Efflux Pump Overexpression Using Phenotypic Methods

Resistance-nodulation-division (RND-type) efflux pump overexpression was tested in the case of ciprofloxacin-resistant isolates, using a phenylalanine-arginine β-naphthylamide (PAβN)-based agar dilution method [47]. During the study, the concentration of PAβN was 40 µg/mL in the agar base; a two-fold decrease in ciprofloxacin MICs (measured by E-tests) in the presence of PAβN, compared to the MIC values without the inhibitor, was considered positive for efflux pump overexpression [47]. P. aeruginosa ATCC 27,853 was used as a control strain.

2.7. Biofilm Production

Biofilm-forming capacity in environmental PA was measured using a microtiter-plate (MTP) method, as described previously [48]. Briefly, overnight P. aeruginosa cultures (grown on Luria–Bertani [LB] agar) were inoculated into 5 mL of LB-broth and incubated overnight at 37 °C. The following day, 180 µL of LB-broth and 20 µL of bacterial suspension set at 10^6 CFU/mL were transferred onto 96-well flat-bottomed microtiter plates to a final volume of 200 µL and incubated for 24 h at 37 °C. Following the incubation period, the supernatants were discarded, and the wells were washed three times using 200 µL of phosphate-buffered saline (pH set at 7.2). After washing, the wells were fixed with 250 µL of methanol (Sigma-Aldrich, St. Louis, MO, USA) for 10 min and stained with a 1.0% crystal violet (CV; Sigma-Aldrich, St. Louis, MO, USA) solution for 15 min. The CV dye was discarded and the wells were washed trice with purified water to remove excess stain. The wells’ contents were solubilized in 250 µL of 33% v/v% glacial acetic acid (Sigma-Aldrich, St. Louis, MO, USA), and a microtiter plate reader was used to measure absorbance at 570 nm (OD570). All experiments were carried out in triplicate. Interpretation of the experimental results was carried out based on the recommendations of Ansari et al.: isolates with OD570 < 0.12 were classified as weak/non-biofilm producers, OD570 = 0.12–0.24 were
classified as moderate biofilm producers, while \( \text{OD}_{570} \) > 0.24 were classified as strong biofilm producers, respectively [49,50].

2.8. Swimming, Swarming, and Twitching Motility

Motility assays were carried out in Petri dishes containing Tryptic Soy Agar medium with different agar concentrations (0.3% for swimming motility, 0.8% for swarming motility, and 2.0% for twitching motility, respectively) [51,52]. Overnight bacterial cultures (set at a density of \( 10^5 \) CFU/mL) were transferred into the agar medium by puncture using a pipette tip (at 1/2 depth for swimming and swarming motility and at full depth for twitching motility) [53]. After incubation at 37 °C for 24 h (swimming and swarming motility) or 48 h (twitching motility), growth zone diameters (mm) were measured; in the case of swimming and swarming motility, the measurements were made directly, while in case of twitching motility, the agar layer was removed and the bottom of the plates was stained directly with 0.01% CV solution [51,52]. All experiments were carried out in triplicate.

2.9. Siderophore Production

Qualitative detection of siderophore production by environmental PA isolates was carried out using the Chrome azurol S (CAS) plate assay, as described previously [54]. Briefly, CAS plates were prepared by adding CAS solution onto melted King’s B agar medium (1:15). Actively-growing cultures of PA were spot-inoculated at the centre of CAS plates. Bacterial colonies exhibiting orange halos after 72 h of incubation (at 28 ± 2 °C) were considered positive for siderophore production [54].

2.10. Statistical Analysis

Descriptive statistical analysis (means with ranges and percentages) was performed using Microsoft Excel 2013 (Microsoft Corp., Redmond, WA, USA). The normality of the variables was assessed using the Kolmogorov–Smirnov test. An independent sample t-test was performed to compare measurements of biofilm-formation (\( \text{OD}_{570} \) measurements) between MDR and non-MDR PA isolates. ANOVA with Tukey’s post hoc test was used to compare growth zones (for swimming, swarming and twitching motility) between different biofilm-producers. The \( \chi^2 \) test was applied to assess the relationship between biofilm formation and siderophore production. Statistical analyses were performed with SPSS software version 22.0 (IBM Corp., Armonk, NY, USA).

3. Results

3.1. Resistance Rates and Resistotypes of Environmental PA Isolates

Resistance levels detected in environmental PA isolates were as follows (in decreasing order): ciprofloxacin 46.98% (\( n = 78 \)), levofloxacin 45.18% (\( n = 75 \)), ceftazidime 31.92% (\( n = 53 \)), cefepime 30.12% (\( n = 50 \)), gentamicin 26.51% (\( n = 44 \)), amikacin 20.48% (\( n = 34 \)), meropenem 10.84% (\( n = 18 \)), imipenem 9.64% (\( n = 16 \)), and colistin 0.60% (\( n = 1 \); MIC > 2 mg/L). The resistotype distribution among environmental PA isolates is presented in Table 1. Overall, seventeen (I–XVII) different resistotypes were identified, with the most numerous resistotypes being VII (resistant to ciprofloxacin, levofloxacin, ceftazidime and cefepime; \( n = 15 \); 9.04%) and VIII (resistant to ciprofloxacin, levofloxacin, gentamicin and amikacin; \( n = 15 \); 9.04%). Of these respective isolates, 19.28% (\( n = 32 \)) met the criteria to be MDR.
### Table 1. Resistotype distribution and MAR indices of environmental PA isolates.

| Resistotype | Resistance Patterns | MAR Index | Ratio of Isolates (n, %) | MDR |
|-------------|---------------------|-----------|--------------------------|-----|
| 0           | None                | 0         | 84 (50.60%)              |     |
| I           | CIP                 | 0.111     | 3 (1.81%)                | non-MDR |
| II          | CEFT                | 0.111     | 3 (1.81%)                |     |
| III         | CIP, LEV            | 0.222     | 9 (5.42%)                |     |
| IV          | CEFT, CEFE          | 0.222     | 1 (0.60%)                |     |
| V           | CIP, LEV, CEFT      | 0.333     | 2 (1.20%)                |     |
| VI          | CIP, LEV, CEFE      | 0.333     | 2 (1.20%)                |     |
| VII         | CIP, LEV, CEFT, CEFE| 0.444     | 15 (9.04%)               |     |
| VIII        | CIP, LEV, GEN, AMI  | 0.444     | 15 (9.04%)               |     |
| IX          | CIP, LEV, CEFT, GEN, CEFE, GEN, AMI | 0.444 | 1 (0.60%) |     |
| X           | CIP, LEV, CEFT, GEN, CEFE, GEN, AMI | 0.555 | 5 (3.01%) |     |
| XI          | CIP, LEV, CEFT, GEN, AMI | 0.555 | 2 (1.20%) | MDR |
| XII         | CIP, LEV, CEFT, CEFE, GEN, AMI | 0.666 | 3 (1.81%) |     |
| XIII        | CIP, LEV, CEFT, CEFE, IMI, MER | 0.666 | 6 (3.62%) |     |
| XIV         | CIP, LEV, CEFT, CEFE, GEN, AMI, MER | 0.777 | 5 (3.01%) |     |
| XV          | CIP, LEV, CEFT, CEFE, GEN, AMI, IMI | 0.777 | 4 (2.42%) |     |
| XVI         | CIP, LEV, CEFT, CEFE, GEN, AMI, IMI | 0.888 | 5 (3.01%) |     |
| XVII        | CIP, LEV, CEFT, CEFE, GEN, IMI, MER, COL | 0.888 | 1 (0.60%) |     |

Abbreviations: CIP: ciprofloxacin, CEFT: ceftazidime, LEV: levofloxacin, CEFE: cefepime, GEN: gentamicin, AMI: amikacin, IMI: imipenem, MER: meropenem, COL: colistin, MDR: multidrug-resistant, MAR: multiple antibiotic resistance.

#### 3.2. AmpC-Overexpression, Carbapenemase-Production, and Overexpression of Efflux Pumps in Environmental PA Isolates

To assess the relevance of various resistance mechanisms contributing to the resistant phenotype in environmental PA isolates, several phenotypic tests were used. Based on the cloxacillin plate test, AmpC overexpression was detected in 56.60% \((n = 30 \text{ out of } 53 \text{ isolates}; 18.07\% \text{ overall})\) of ceftazidime-resistant isolates. Carbapenemase production was detected using the modified Hodge-test: the test was positive in 28.57% \((n = 6, \text{ out of } 21 \text{ isolates meeting inclusion criteria}; 3.61\% \text{ overall})\) of cases. Overexpression of RND-type efflux pumps—ascertained in case of detected ciprofloxacin resistance—was noted in 60.26% \((n = 47, \text{ out of } 78 \text{ isolates}; 28.31\% \text{ overall})\). Simultaneous detection of resistance mechanisms was as follows: efflux pump and AmpC overexpression in \(n = 14\) isolates, efflux pump overexpression and cloverleaf-test positivity in \(n = 1\) isolate, cloverleaf-test positivity and AmpC overexpression in \(n = 1\) isolate, while detection of all three mechanisms was seen in \(n = 2\) isolates, respectively.

#### 3.3. Biofilm-Forming Capacity and the Relationship with Phenotypic Expression of Virulence Factors

The biofilm-forming capacity of the environmental isolates was ascertained using a microplate-based assay with CV-staining, where results were expressed after spectrophotometric measurements (OD\(_{570}\)). PA PAE 170022 (positive control) presented with OD\(_{570}\) values of 0.401 ± 0.089, while PA ATCC 27853 (negative control) had OD\(_{570}\) values of 0.072 ± 0.006. Based on the CV-assay, 22.89% \((n = 38)\) of isolates were weak/non-biofilm producers, 27.71% \((n = 46)\) were moderate biofilm producers, while 49.40% \((n = 82)\) were...
strong biofilm producers, respectively. Based on the MDR status of the isolates, no significant differences in biofilm-production were shown among environmental PA (OD\textsubscript{570} values non-MDR [mean ± SD]: 0.416 ± 0.167 vs. MDR: 0.399 ± 0.192; \( p > 0.05 \)); the same was true when biofilm-forming capacity was compared on an individual antibiotic-level, as no significant differences were seen in OD\textsubscript{570} values (data not shown).

Results of the motility assays—in the context of the biofilm-forming capacity of the isolates—are presented in Table 2. Levels of motility (expressed in mm) were highest for swarming, then swimming and twitching motility, respectively. Neither of the motility types showed significant differences based on the biofilm-production levels of the isolates (\( p > 0.05 \) in all cases). No significant association was shown for motility in regards to the drug resistance phenotype (swimming: non-MDR: 24.51 ± 7.25 vs. MDR: 23.06 ± 8.03; \( p > 0.05 \); swarming: non-MDR: 28.11 ± 6.11 vs. MDR: 26.94 ± 5.97; \( p > 0.05 \); twitching: non-MDR: 10.43 ± 2.43 vs. MDR: 9.78 ± 2.82; \( p > 0.05 \)). The majority of isolates (\( n = 138; \) 83.13%) tested were positive for siderophore production; no statistical association was shown between biofilm-production levels and siderophore production (Table 3.)

### Table 2. Relationship between biofilm-formation and motility in environmental PA isolates.

| Motility             | Weak/Non-Biofilm Producers (\( n = 38 \)) | Moderate Biofilm Producers (\( n = 46 \)) | Strong Biofilm Producers (\( n = 82 \)) | Statistics |
|----------------------|-------------------------------------------|-------------------------------------------|----------------------------------------|------------|
| Swimming motility (mm) (mean ± SD) | 24.66 ± 8.96 | 23.87 ± 7.01 | 25.15 ± 6.94 | n.s. |
| Swarming motility (mm) (mean ± SD) | 27.98 ± 6.02 | 27.44 ± 6.43 | 28.76 ± 5.40 | n.s. |
| Twitching motility (mm) (mean ± SD) | 11.07 ± 3.65 | 10.88 ± 2.96 | 10.23 ± 2.13 | n.s. |

n.s.: not statistically significant.

### Table 3. Relationship between biofilm-formation and siderophore production in environmental PA isolates.

| Siderophore-Producers | Weak/Non-Biofilm Producers (\( n = 38 \)) | Moderate Biofilm Producers (\( n = 46 \)) | Strong Biofilm Producers (\( n = 82 \)) | Statistics |
|-----------------------|-------------------------------------------|-------------------------------------------|----------------------------------------|------------|
| Siderophore (+)       | 27 | 39 | 72 | n.s. |
| n = 138               |               |               |               |            |
| Siderophore (−)       | 11 | 7  | 10 | n.s. |
| n = 28                |               |               |               |            |

n.s.: not statistically significant.

### 4. Discussion

PA is an important causative agent of acute and chronic infections primarily in elderly, hospitalized individuals, and in patients affected by immunosuppression (e.g., antitumor therapy), underlying conditions (e.g., cystic fibrosis [CF]) or invasive medical interventions [2,20,55]. Overall mortality associated with these infections may be as high as 20–60%, which is further compounded by the increasing levels of MDR in PA [56]. The hallmarks of PA’s pathogenicity include its cell-mediated (endotoxin, flagella, pili, and adhesins) and secreted virulence determinants (type I–III secretion systems, degrading enzymes, and exotoxins) [2,57]. Biofilm may be considered another critical secreted virulence factor, which allows for the survival of their host; biofilms have a complex composition including aggregated bacteria, carbohydrates (among them, exopolysaccharides are the most
important), DNA, lipids, proteins, and ions, which all have a role in binding water to this matrix [38, 59]. Many environmental bacteria owe their recalcitrance to biofilms, which may provide protection against dryness, salt stress, extreme pH, temperature shocks, a scarcity of nutrients, or toxic xenobiotics [60]. Diffusion of unwanted molecules into the biofilms may be reduced $10^1$–$10^6$-fold, compared to the diffusion rate around planktonic cells [61]. Based on a meta-analysis of existing studies, 75–99% of PA tested in some phenotypic biofilm-assay were biofilm-producers, out of which, 8–50% were classified as potent biofilm-forming isolates [25].

Members of *Pseudomonas* spp. have been highlighted from a “One Health” perspective [62]: on one hand, they have been implicated as possible zoonotic (avian) pathogens, while environmental isolates have also been suggested as possible reservoirs of antibiotic resistance genes [63, 64]. Since then, an increasing number of reports describe the characterization of the resistance and virulence of environmental PA isolates [65]. In our present study, we aimed to assess biofilm-forming capacity in the context of MDR and other phenotypic virulence factors, based on experiments related to environmental PA isolates. Over two-thirds (77.11%) of isolates in our sample produced biofilm, while ~50% were strong biofilm-producers; interestingly, biofilm-producers in general and strong biofilm-producers were more common among clinical isolates (80.13% and 59.27%, respectively). When compared with our previous results for clinical PA isolates [32], resistance against fluoroquinolones was the most common in isolates of both origins; on the other hand, resistance against β-lactams, aminoglycosides and the prevalence of MDR isolates was considerably higher among clinical PA. Similar to the case of clinical isolates, looking for an association between biofilm production and other study correlates largely ended up in negative results [32]. MDR status or resistance to individual antibiotics did not predict biofilm-forming capacity, in addition to finding no significant differences in motility or siderophore production in isolates with different biofilm-forming capacities.

Radó et al. characterized PA isolated from hydrocarbon or polycyclic aromatic hydrocarbon-contaminated areas using a multi-locus sequence typing (MLST) scheme [66]; they have found isolates belonging to the ST-253 (belonging to the clonal complex PA14, which are high-risk clones with a propensity to become MDR) and ST-198 (associated with CF) sequence types, and seven different serotypes were detected. All isolates carried three virulence genes (*exoY, exoT, and exoA*), while many carried the additional two genes (*exoS and exol*) as well. The study did not find an association between biofilm formation and drug resistance, although most of the isolates were moderate or strong producers of biofilm [66]. In the study of Kaszab et al., $n = 44$ isolates from a similar origin were included in analyses [35]; in contrast to our findings, these isolates showed higher levels of resistance against β-lactam antibiotics, while retained susceptibility for ciprofloxacin and gentamicin; 9.1% were MDR. Nine serotypes were detected, while based on pulse-field gel electrophoresis (PFGE) analyses, several environmental strains showed considerable homology with clinical isolates. 61.3% of isolates were biofilm-producers, and 79.0% carried five out of the six virulence genes tested. The virulence potential of the isolates was also tested via a *Galleria mellonella* infection model: almost two-thirds of the isolates were virulent, demonstrating a mortality rate of 75–100% in the wax moth model. Biofilm-formation had no relevant relationship with drug resistance or virulence, while the lack of motility and the lack of *exoS/exol* genes led to significantly reduced virulence [35]. Adhimi et al. characterized the diversity of pseudomonads in water dams, during which they found 21 distinct species; while resistance against amoxicillin-clavulanic acid (~67%), cefoxitin (~94%), streptomycin (~58%) and fosfomycin (~64%) were high, no resistant isolates were found towards the antibiotics included in the present study. Out of the 13 virulence genes tested, 12 were found in all isolates, while the *exol* gene was noted in 5.8% of isolates. Although the authors did not detect any Class I or II integrons in these isolates, the authors highlighted environmental *Pseudomonas* spp. as possible reservoirs of MDR genes [67]. Thomassen et al. performed the microbiological sampling of a salmon processing facility, during which a considerable number of *Pseudomonas* spp. isolates were found. A large portion of these...
isolates (86%) were classified as MDR, and based on whole-genome sequencing (WGS) analyses, efflux pumps may have been important contributors to phenotypic resistance [68].

The study of Liew et al. included $n = 215$ PA isolates of both clinical and environmental origins, collected over a period of thirty years [69]; resistance rates were low, 2.6%, 8.8% and 11.4% of isolates were resistant to imipenem, meropenem, and doripenem, respectively, while some resistant isolates harboured none of the virulence genes tested. The prevalence of virulence genes in environmental isolates was similar to the ones detected from clinical isolates, suggesting that aquatic environments may be potential sources of PA infections. As previously mentioned, Gallant et al. showed that the presence of a specific resistance determinant (a β-lactamase) in PA was associated with decreased biofilm-forming capacity in these isolates [31]. Similar to our studies, Eladawy et al. also did not find an association between the drug-resistant phenotype, the presence of 11 out of 13 virulence genes (with the exception of pelA and phzM), and biofilm-formation among $n = 103$ clinical PA isolates [70]. These results are also in line with the findings of Milojkovic et al., who also did not find a significant correlation between biofilm-production and other relevant correlates (e.g., virulence and AMR-genes, production of pigment, serotypes) in PA [71]. Interestingly, both the studies of Choy et al. [72] and Bahador et al. [73] have described that the presence of various virulence genes (exoU alone, or exoU and exoS)—but not the MDR phenotype or resistance to individual antimicrobials—was a reliable predictor of strong biofilm-forming capacity.

In contrast to our study and the findings of Gallant et al. [31], Perez et al. reported that PA isolates originating from CF patients produced a more robust biofilm, in case of the carriage of a metallo-β-lactamase [74], while Zahedani et al. described a similar positive association between biofilm-formation and the expression of efflux pumps [75]. Additionally, several studies have described a remarkable relationship between the MDR (or XDR) phenotype and the capacity to form biofilm: the studies of Abidi et al. (involving PA from eye infections [76]), Kaiser et al. (involving isolates from both hospital and environmental samples [77]) and Karami et al. (involving isolates from both hospital and environmental samples [78]) have all demonstrated that strong biofilm-formation was strongly associated with the MDR status of the isolates. In the report by Karami et al., environmental PA isolates showed considerable resistance rates to many β-lactams and aminoglycosides, but retained susceptibility to colistin [78]. There may be some mechanistic explanations for this, as Kaiser et al. noted that isolates exhibiting extensive resistance were more vulnerable to serum killing and polymorphonuclear neutrophil (PMN) killing in vitro [77]. Interestingly, while Rodulfo et al. [79] did not find an association between the MDR/XDR phenotype, biofilm-formation, and pigment production in clinical PA, the presence of the exoU gene (carried by 38.1% of isolates), hemolysin-production showed significant positive, while twitching motility showed negative correlation with MDR/XDR status.

For clarity, the limitations of our study must be acknowledged: firstly, the cross-sectional nature of the study—which included isolates from a wide range of sources—but may not reflect PA from other environments. The origin, genetic composition, and sampling methods may have considerable influence in these studies, often leading to differences in results [80]. Additionally, the study employed phenotypic methods only to assess the resistance rates, virulence, and biofilm production of these isolates. For example, a quantitative, spectrophotometric, plate-based method was used to quantify biofilm-production, however, the literature reports numerous, more advanced, quantitative in vitro, and in vivo animal models, biosensors and flow chambers that allow for the testing of biofilm-production in conditions much closer to “real life” circumstances. The interpretation of several phenotypic assays was carried out visually, thus, the description of the results may be influenced by the expertise of the researchers. The lack of molecular biological methods (PCR, MLST, sequencing) employed is a considerable limitation of the study; therefore, we do not have information regarding the genetic origin (e.g., the clonal lineage) of the isolates, the presence and expression levels of the biofilm, virulence and/or resistance genes, or the genotype-phenotype relationship in PA. As the regulation of the cellular and metabolic
processes (e.g., expression of virulence factors) may differ considerably among genera, the generalization of results among different bacteria is also limited [81]. For example, during a similar biofilm-related study on environmental Staphylococcus spp., no correlation was observed between MDR and biofilm formation, while a significant association was found between rifampicin resistance and strong biofilm-producers [82]. Within its limitations, our study has provided additional data on the relationship between antibiotic resistance, biofilm-forming capacity, and other relevant virulence factors. Our experiments with environmental PA have confirmed our previous findings with clinical isolates [32], i.e., the MDR phenotype and/or resistance to specific antibiotics did not have a significant relationship with biofilm-forming capacity or the phenotypic expression of virulence determinants. However, as demonstrated by earlier studies described previously, evidence in this field is still inconclusive; the use of different models to test biofilm formation may considerably inform the heterogeneity of the available results [83]. The importance of PA as a pathogen in chronic and healthcare-associated infections has been described extensively, while there is increasing awareness of PA as an environmental agent in agriculture and aquaculture. Therapy of PA infections is increasingly difficult due to the increasing number of MDR isolates, the eradication of these microorganisms is further compounded by the protective biofilm, both in vivo and in natural or industrial environments [84]. Therefore, additional studies in this field would be an important undertaking to understand the interrelated nature of biofilm production and antimicrobial resistance, as these insights may become relevant bases for developing novel therapeutics and eradication strategies against PA.

**Author Contributions:** Conceptualization: P.B., M.G., and M.G.D.; Methodology: P.B., M.G., K.B., and A.K.; Formal analysis: M.G., P.P., B.O., B.B., M.F., C.D., G.C., A.K., and M.G.D.; Investigation: M.G., P.P., B.O., B.B., M.F., C.D., G.C., A.K., and M.G.D.; Resources: K.B., A.S., K.K., and D.M.; Supervision: M.G., K.B., and S.Z.; Project administration: M.G., A.S., K.K., and D.M.; Funding acquisition: M.G., A.S., S.Z., and M.G.D.; Writing—original draft: M.G. and M.G.D.; Writing—review and editing: P.B., M.G., A.K., and M.G.D. All authors have read and agreed to the published version of the manuscript.

**Funding:** M.G. was supported by the János Bolyai Research Scholarship (BO/00144/20/5) of the Hungarian Academy of Sciences. The research was supported by the New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research Development and Innovation Fund (M.G.: ÚNKP-22-5-SZTE-107; P.P.: ÚNKP-22-2-SZTE-103; B.Ö.: ÚNKP-22-2-SZTE-102). M.G.D., C.D., G.C. and S.Z. were supported by the Sardinia Foundation, code project: 2020.1339.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and national and institutional ethical standards. Ethical approval for the study protocol was obtained from the Human Institutional and Regional Biomedical Research Ethics Committee, University of Szeged (registration number: 140/2021-SZTE [5019].

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data generated during the study are presented in this paper.

**Acknowledgments:** M.G. would like to acknowledge the support of ESCMID’s “30 under 30” Award.

**Conflicts of Interest:** The authors declare no conflict of interest, monetary or otherwise. The authors alone are responsible for the content and writing of this article.

**References**

1. LPSN—List of Prokaryotic names with Standing in Nomenclature. Genus Pseudomonas. Available online: https://lpsn.dsmz.de/genus/pseudomonas (accessed on 12 July 2022).
2. Behzadi, P.; Barath, Z.; Gajdacs, M. It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics 2021, 10, 42. [CrossRef]
3. Kumar, H.; Franzetti, L.; Kaushal, A.; Kumar, D. Pseudomonas fluorescens: A potential food spoiler and challenges and advances in its detection. Ann. Microbiol. 2019, 69, 873–883.
4. Gutiérrez-Barranquero, J.A.; Cazorla, F.M.; de Vincente, A. Pseudomonas syringae pv. syringae Associated with Mango Trees, a Particular Pathogen Within the “Hodgepodge” of the Pseudomonas syringae Complex. Front. Plant Sci. 2019, 10, e570.
5. Duman, M.; Mulet, M.; Altun, S.; Saticioglu, I.B.; Ozdemir, B.; Ajmi, N.; Lalucat, J.; García-Valdés, E. The diversity of Pseudomonas species isolated from fish farms in Turkey. *Aquaculture* 2021, 535, e736369. [CrossRef]

6. Nolan, L.M.; Turnbull, L.; Katrib, M.; Osvalth, S.R.; Losa, D.; Lazenby, J.J.; Withbcurn, C.B. *Pseudomonas aeruginosa* is capable of natural transformation in biofilms. *Microbiology* 2020, 166, 995–1003. [CrossRef]

7. Fernández, M.; Porcel, M.; de la Torre, J.; Molina-Henares, M.A.; Daddaoua, A.; Llamas, M.A.; Roca, A.; Carriel, V.; Garzón, I.; Ramos, J.L.; et al. Analysis of the pathogenic potential of nosocomial *Pseudomonas putida* strains. *Front. Microbiol.* 2015, 6, e871. [CrossRef]

8. Moradali, M.F.; Ghods, S.; Rehm, B.H.A. *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front. Cell. Infect. Microbiol.* 2017, 7, e39.

9. Vodovar, N.; Vallenet, D.; Cruveiller, S.; Rouy, Z.; Barbe, V.; Acosta, C.; Cattolico, L.; Cubin., C.; Lajus, A.; Seguren; B.; et al. Complete genome sequence of the entomopathogenic and metabolically versatile soil bacterium *Pseudomonas entomophila*. *Nat. Biotechnol.* 2006, 24, 673–679.

10. Bao, Z.; Stodghill, P.V.; Myers, C.R.; Lam, H.; Wei, H.L.; Charavarthy, S.; Kvitko, B.H.; Collmer, A.; Cartinhour, S.W.; Schweitzer, P.; et al. Genomic Plasticity Enables Phenotypic Variation of *Pseudomonas syringae* pv. tomato DC3000. *PLoS ONE* 2014, 9, e8662.

11. Kazmierczak, B.I.; Schnierderberend, M.; Jain, R. Cross-regulation of *Pseudomonas* motility systems: The intimate relationship between flagella, pili and virulence. *Curr. Opin. Microbiol.* 2015, 28, 78–82.

12. Maurice, N.M.; Bedi, B.; Sadikot, R.T. *Pseudomonas aeruginosa* Biofilms: Host Response and Clinical Implications in Lung Infections. *Am. J. Respir. Cell Mol. Biol.* 2018, 58, 428–439. [CrossRef]

13. Chen, H.; Wubbolts, R.W.; Haagsman, H.P.; Weldhuizen, E.J.A. Inhibition and Eradication of *Pseudomonas aeruginosa* Biofilms by Host Defence Peptides. *Sci. Rep.* 2018, 8, e10446.

14. Uddin, T.M.; Chakraborty, A.J.; Khusro, A.; Zidan, B.R.M.; Mitra, S.; Emran, T.B.; Dham, K.; Ripon, K.H.M.; Gajdács, M.; Sahibzada, M.U.K.; et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. *J. Infect. Pub. Health* 2021, 14, 1750–1766.

15. Mares, C.; Petca, R.C.; Petca, A.; Popescu, R.I.; Jinga, V. Does the COVID Pandemic Modify the Antibiotic Resistance of Uropathogens in Female Patients? A New Storm? *Antibiotics* 2022, 11, 376. [CrossRef]

16. Petca, R.C.; Negoi, S.; Mares, C.; Petca, A.; Popescu, R.I.; Chibelean, C.B. Heterogeneity of Antibiotics Multidrug-Resistance Profile of Uropathogens in Romanian Population. *Antibiotics* 2021, 10, 523.

17. Global Antibiotic Research and Development Partnership (GARDP): GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance. Available online: http://www.gardp.org/news-resources/gardp-and-carb-x-welcome-renewed-commitment-by-g7-leaders-to-address-antimicrobial-resistance/ (accessed on 12 July 2022).

18. Zhang, Y.; Li, Y.; Zeng, J.; Chang, Y.; Han, S.; Zhao, J.; Fan, Y.; Xiong, Z.; Zou, X.; Wang, C.; et al. Risk Factors for Mortality of Inpatients with *Pseudomonas aeruginosa* Bacteremia in China: Impact of Resistance Profile in the Mortality. *Infect. Drug Res.* 2020, 13, 4115–4123.

19. Zilahi, G.; Artigas, A.; Loeches-Martín, I. What’s new in multidrug-resistant pathogens in the ICU? *Ann. Intensive Care* 2016, 6, e96.

20. Bentzmann, S.; Pléüat, P. The *Pseudomonas aeruginosa* opportunistic pathogen and human infections. *Environ. Microbiol.* 2011, 13, 1655–1665.

21. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.J.; Cheng, Z. Antibiotic resistance in *Pseudomonas aeruginosa*: Mechanisms and alternative therapeutic strategies. *Biotechnol. Adv.* 2019, 37, 177–192.

22. Centers for Disease Control and Prevention (CDC): *Pseudomonas aeruginosa* in Healthcare Settings. Available online: https://www.cdc.gov/healthcare-associated-infections/organisms/pseudomonas.html (accessed on 12 July 2022).

23. European Centre for Disease Prevention and Control (ECDC): Antimicrobial resistance surveillance in Europe 2022–2020 data. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/ECDC-WHO-AMR-report.pdf (accessed on 12 July 2022).

24. World Health Organization (WHO): WHO publishes list of bacteria for which new antibiotics are urgently needed. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 12 July 2022).

25. Mirza, H.K.; Hadadi-Fishani, M.; Morshed, K.; Khaleeli, A. Meta-analysis of biofilm formation, antibiotic resistance pattern, and biofilm-related genes in *Pseudomonas aeruginosa* isolated from clinical samples. *Microb. Drug Resist.* 2020, 26, 815–824.

26. Cepas, V.; López, Y.; Munoz, E.; Rolo, D.; Ardanuy, C.; Martí, M.; Xercavins, M.; Horcajada, J.P.; Bosch, J.; Soto, S.M. Relationship Between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria. *Microb. Drug Res.* 2019, 25, 72–83.

27. Hacker, J.; Blum-Oehler, G.; Muhldorfer, I.; Tschape, H. Pathogenicity islands of virulent bacteria: Structure, function and impact on microbial evolution. *Mol. Microbiol.* 1997, 23, 1089–1097. [CrossRef]

28. Pandey, R.; Mishra, S.K.; Shrestha, A. Characterisation of ESKEAPE Pathogens with Special Reference to Multidrug Resistant and Biofilm Production in a Nepalese Hospital. *Infect. Drug Res.* 2021, 14, 2201–2212.

29. Zhao, F.; Yang, H.; Bi, D.; Khaleeli, A.; Qiao, M. A systematic review and meta-analysis of antibiotic resistance patterns, and the correlation between biofilm formation with virulence factors in uropathogenic *E. coli* isolated from urinary tract infections. *Microb. Pathogen.* 2020, 144, e104196.
12. Azizi, O.; Shaheheraghi, F.; Salimzand, H.; Modarresi, F.; Shakibaie, M.R.; Mansouri, S.; Ramazanzadeh, R.; Badmasti, F.; Nikbin, V. Molecular Analysis and Expression of bap Gene in Biofilm-Forming Multi-Drug-Resistant Acinetobacter baumannii. Rep. Biochem. Mol. Biol. 2016, 5, 62–72.

21. Gallant, C.V.; Daniels, C.; Leung, J.M.; Ghosh, A.S.; Young, K.D.; Kotra, L.P.; Burrows, L.L. Common β-lactamases inhibit bacterial biofilm formation. Mol. Microbiol. 2005, 58, 1012–1024.

23. Gajdács, M.; Baráth, Z.; Kárpáti, K.; Szabó, D.; Usai, D.; Zanetti, S.; Donadu, M.G. No Correlation between Biofilm Formation, Virulence Factors, and Antibiotic Resistance in Pseudomonas aeruginosa: Results from a Laboratory-Based In Vitro Study. Antibiotics 2021, 10, e1134.

28. Odongo, I.; Ssemambo, R.; Kungu, J.M. Prevalence of Escherichia coli and its antimicrobial susceptibility profiles among patients with UTI at Mulago Hospital, Kampala, Uganda. Int. Persp. Infect. Dis. 2020, 2020, e804250.

31. Kaszab, E.; Radó, J.; Kriszt, B.; Pászti, J.; Lesinszki, V.; Szabo, Á.; Tóth, G.; Khaledi, A.; Szoboszlay, S. Groundwater, soil and compost, as possible sources of virulent and antibiotic-resistant Pseudomonas aeruginosa. Int. J. Environ. Health Res. 2021, 31, 848–860.

33. Schubert, S.; Kostrzewa, M. MALDI-TOF MS in the microbiology laboratory: Current trends. Curr. Issues Mol. Biol. 2017, 23, 17–20. [CrossRef] [PubMed]

35. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoints and Dosing. Available online: https://www.eucast.org/clinical_breakpoints/ (accessed on 10 June 2022).

36. Saeki, E.K.; Yamada, A.Y.; de Araujo, L.A.; Anversa, L.; Garcia, D.D.O.; de Souza, R.L.B.; Martins, H.M.; Kobayashi, R.K.T.; et al. For veterinary medicine. Vet. Record. 2001, 148, 567–572.

37. European Committee on Antimicrobial Susceptibility Testing (EUCAST). New Definitions of S, I and R from 2019. Available online: https://www.eucast.org/newsiandr/ (accessed on 10 June 2022).

38. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoints and Dosing. Available online: https://www.eucast.org/clinical_breakpoints/ (accessed on 10 June 2022).

41. Saeki, E.K.; Yamada, A.Y.; de Araujo, L.A.; Anversa, L.; Garcia, D.D.O.; de Souza, R.L.B.; Martins, H.M.; Kobayashi, R.K.T.; Nakazato, G. Subinhibitory concentrations of biogenic silver nanoparticles affect motility and biofilm formation in Pseudomonas aeruginosa. Front. Cell. Infect. Microbiol. 2021, 11, e656984.

46. Akhi, M.T.; Khalili, Y.; Chotaslou, R.; Yousefi, S.; Kafil, H.S.; Naghili, B.; Sheikhalizadeh, V. Evaluation of carbapenem resistance in Pseudomonas aeruginosa. In Pseudomonas aeruginosa: Epidemiology and Clinical Implications; Nikbin, V., Ghandehari, F., Eds.; Humana Press Inc.: New York, NY, USA, 2014; pp. 73–86.

47. Vera-Leiva, A.; Carrasco-Anabalón, S.; Lima, C.A.; Villagrasa, N.; Domínguez, M.; Bello-Toledo, H.; González-Rocha, G. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae. J. Glob. Antimicrob. Res. 2018, 12, 73–76.

48. Chou, C.-H.; Lai, Y.-R.; Chi, C.-Y.; Ho, M.-W.; Chen, C.-L.; Liao, W.-C.; Ho, C.-M.; Chen, Y.-A.; Chen, C.-Y.; Lin, Y.-T.; et al. Long-term surveillance of antibiotic prescriptions and the prevalence of antimicrobial resistance in non-fermenting gram-negative bacilli. Microorganisms 2020, 8, e656984.

49. Akhi, M.T.; Khalili, Y.; Chotaslou, R.; Yousefi, S.; Kafil, H.S.; Naghili, B.; Sheikhhalizadeh, V. Evaluation of carbapenem resistance mechanisms and its association with Pseudomonas aeruginosa infection in the northwest of Iran. Microb. Drug Res. 2018, 24, 126–135.

50.Vec-Leiva, A.; Carrasco-Anabalón, S.; Lima, C.A.; Villagrasa, N.; Domínguez, M.; Bello-Toledo, H.; González-Rocha, G. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae. J. Glob. Antimicrob. Res. 2018, 12, 73–76.

51. Ramos-Vivas, J.-L., Eds.; Humana Press Inc.: New York, NY, USA, 2014; pp. 73–86.
80. Atzél, B.; Szoboszlay, S.; Mikuska, Z.; Kriszt, B. Comparison of phenotypic and genotypic methods for the detection of environmental isolates of *Pseudomonas aeruginosa*. *Int. J. Hyg. Environ. Health* 2008, 211, 143–155. [CrossRef] [PubMed]

81. Alshanta, O.A.; Albashaireh, K.; McCloud, E.; Delaney, C.; Kean, R.; McLean, W.; Ramage, G. *Candida albicans* and *Enterococcus faecalis* biofilm frenemies: When the relationship sours. *Biofilm* 2022, 4, e100072. [CrossRef] [PubMed]

82. Donadu, M.G.; Ferrari, M.; Mazzarello, V.; Zanetti, S.; Kushkevych, I.; Rittmann, S.K.M.R.; Stäjer, A.; Baráth, Z.; Szabó, D.; Urbán, E.; et al. No Correlation between Biofilm-Forming Capacity and Antibiotic Resistance in Environmental *Staphylococcus* spp.: In Vitro Results. *Pathogens* 2022, 11, 471. [CrossRef] [PubMed]

83. Vyas, H.K.N.; Xia, B.; Mai-Prochnow, A. Clinically relevant in vitro biofilm models: A need to mimic and recapitulate the host environment. *Biofilm* 2022, 4, e100069. [CrossRef]

84. Sindeldecker, D.; Stoodley, P. The many antibiotic resistance and tolerance strategies of *Pseudomonas aeruginosa*. *Biofilm* 2021, 3, e100056. [CrossRef]